Program
SCTB39G
A development code. Also written as “SCTB41+SCTB39G”.
Its studies are led by Sinocelltech Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 22 open or running | phase 2since Jul 11, 2025 | Jul 11, 2025 | Sep 26, 2027phase 2 · NCT07077252 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2025First study: phase 2 study in Advanced Malignant Solid TumorFirst studyNCT07077252 · 30 planned · China
- Jun 18, 2026Phase 2 study in Advanced Malignant Solid TumorsNCT07665970 · 112 planned
Ahead
- Sep 26, 2027Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07077252
- Jun 30, 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorsNCT07665970
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07665970Advanced Malignant Solid Tumors | 2 | Not yet recruiting | Jun 30, 2029 | 112 |
| NCT07077252Advanced Malignant Solid Tumor · China | 2 | Not yet recruiting | Sep 26, 2027 | 30 |
How it is read
Names in the registry
- “SCTB41+SCTB39G”, 1 entry
- “SCTB39G”, 1 entry
Codes read as this program: SCTB39G.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.